Abstract
Smad3 is an essential component in the intracellular signaling of transforming growth factor-β (TGFβ), which is a potent inhibitor of tumor cell proliferation. BRCA2 is a tumor suppressor involved in early onset of breast, ovarian and prostate cancer. Both Smad3 and BRCA2 possess transcription activation domains. Here, we show that Smad3 and BRCA2 interact functionally and physically. We found that BRCA2 forms a complex with Smad3 in vitro and in vivo, and that both MH1 and MH2 domains of Smad3 contribute to the interaction. TGFβ1 stimulates interaction of endogenous Smad3 and BRCA2 in non-transfected cells. BRCA2 co-activates Smad3-dependent transcriptional activation of luciferase reporter and expression of plasminogen activator inhibitor-1 (PAI-1). Smad3 increases the transcriptional activity of BRCA2 fused to the DNA-binding domain (DBD) of Gal4, and reciprocally, BRCA2 co-activates DBD-Gal4-Smad3. Thus, our results show that BRCA2 and Smad3 form a complex and synergize in regulation of transcription.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, Kawabata M . 1999 J. Biol. Chem. 274: 35269–35277
Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashwoth A . 1997 Nat. Genet. 17: 423–430
Chen X, Rubock MJ, Whitman M . 1996 Nature 383: 691–696
de Caestecker M, Piek E, Roberts AB . 2000 J. Natl. Cancer Inst. 92: 1388–1402
Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier J-M . 1998 EMBO J. 17: 3091–3100
Fuks F, Milner J, Kouzarides T . 1998 Oncogene 17: 2531–2534
Hanahan D, Weinberg R . 2000 Cell 100: 57–70
Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y . 1999 J. Biol. Chem. 274: 31577–31582
Hofmann W, Schlag PM . 2000 J.Cancer Res. Oncol. 126: 487–496
Hua X, Liu X, Ansari DO, Lodish HF . 1998 Genes Dev. 12: 3084–3095
Itoh S, Ericsson J, Nishikawa J, Heldin C-H, ten Dijke P . 2000 Nucleic Acids Res. 28: 4291–4298
Jonk LJ, Itoh S, Heldin C-H, ten Dijke P, Kruijer W . 1998 J. Biol. Chem. 273: 21145–21152
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H . 1998 Nature 394: 92–96
Laiho M, Saksela O, Keski-Oja J . 1987 J. Biol. Chem. 262: 17467–17474
Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, Wang X-F . 1999 Proc. Natl. Acad. Sci. USA 96: 4844–4849
Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A . 1997 Genes Dev. 11: 1226–1241
Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K . 1987 EMBO J. 6: 1281–1286
Marmorstein LY, Ouchi T, Aaronson A . 1998 Proc. Natl. Acad. Sci. USA. 95: 13869–13874
Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T . 1997 Nature 386: 772–773
Miyazono K, ten Dijke P, Heldin C-H . 2000 Adv. Immun. 75: 115–157
Moustakas A, Kardassis D . 1998 Proc. Natl. Acad. Sci. USA 95: 6733–6738
Nordling M, Karsson P, Wahlstrom J, Engwall Y, Wallgren A, Martinsson T . 1998 Cancer Res. 58: 1372–1375
Pardali E, Xie X-Q, Itoh S, Konstantinos A, Panagiotis T, Heldin C-H, ten Dijke P, Gundström T, Sideras P . 2000 J. Biol. Chem. 275: 3552–3560
Piek E, Heldin C-H, ten Dijke P . 1999 FASEB J. 13: 2105–2124
Scully R, Livingston DM . 2000 Nature 408: 429–432
Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma I . 1999 Proc. Natl. Acad., Sci. USA 96: 13920–13925
Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K . 1999 Science 286: 771–774
Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA . 1999 Mol. Cell 4: 499–509
Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A . 1998 Proc. Natl. Acad. Sci. USA 95: 14769–14774
Yakymovych I, ten Dijke P, Heldin C-H, Souchelnytskyi S . 2001 FASEB J. 15: 553–555
Zawel L, LeDai J, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern S . 1998 Mol. Cell 1: 611–617
Zhang Y, Feng X-H, Derynck R . 1998 Nature 394: 909–913
Acknowledgements
We are thankful to Johan Ericsson for valuable discussions, and to Francois Fuks, Tony Kouzarides and Inder Verma for BRCA2 constructs. This work was supported in part by grants of the Royal Swedish Academy of Sciences, the INSERM/MFR/VR and the EU-program on angiogenesis to Serhiy Souchelnytskyi. Takashi Kanamoto was supported by the Swedish Foundation for International Cooperation in Research and Higher Education (STINT).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Preobrazhenska, O., Yakymovych, M., Kanamoto, T. et al. BRCA2 and Smad3 synergize in regulation of gene transcription. Oncogene 21, 5660–5664 (2002). https://doi.org/10.1038/sj.onc.1205732
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205732
Keywords
This article is cited by
-
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers
Breast Cancer Research (2010)
-
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers
Breast Cancer Research and Treatment (2008)
-
BRCA2 is required for neurogenesis and suppression of medulloblastoma
The EMBO Journal (2007)
-
TGFβ1/Smad3 counteracts BRCA1-dependent repair of DNA damage
Oncogene (2005)